WT1, MSH6, GATA5 and PAX5 as epigenetic oral squamous cell carcinoma biomarkers - a short report
- 305 Downloads
Oral squamous cell carcinoma (OSCC) is a frequently occurring aggressive malignancy with a heterogeneous clinical behavior. Based on the paucity of specific early diagnostic and prognostic biomarkers, which hampers the appropriate treatment and, ultimately the development of novel targeted therapies, we aimed at identifying such biomarkers through a genetic and epigenetic analysis of these tumors.
93 primary OSCCs were subjected to DNA copy number alteration (CNA) and methylation status analyses using methylation-specific multiplex ligation-dependent probe amplification (MS-MPLA). The genetic and epigenetic OSCC profiles obtained were associated with the patients’ clinic-pathological features.
We found that WT1 gene promoter methylation is a predictor of a better prognosis and that MSH6 and GATA5 gene promoter methylation serve as predictors of a worse prognosis. GATA5 gene promoter methylation was found to be significantly associated with a shorter survival rate. In addition, we found that PAX5 gene promoter methylation was significantly associated with tongue tumors. To the best of our knowledge, this is the first study that highlights this specific set of genes as epigenetic diagnostic and prognostic biomarkers in OSCC.
Our data highlight the importance of epigenetically assessing OSCCs to identify key genes that may serve as diagnostic and prognostic biomarkers and, potentially, as candidate therapeutic targets.
KeywordsDNA methylation Copy number gains and losses Predictors of prognosis Oral squamous cell carcinoma
Ribeiro I.P. is a recipient of a PhD fellowship (SFRH/BD/52290/2013) from the Portuguese Foundation for Science and Technology. This work was in part supported by CIMAGO (Center of Investigation on Environment Genetics and Oncobiology - Faculty of Medicine, University of Coimbra) and by the Portuguese Foundation for Science and Technology (grant: UID/NEU/04539/2013).
Compliance with ethical standards
Conflict of interest
The authors have no conflict of interest to disclose.
- 1.L. M. Arantes, A. C. de Carvalho, M. E. Melendez, C. C. Centrone, J. F. Gois-Filho, T. N. Toporcov, D. N. Caly, E. H. Tajara, E. M. Goloni-Bertollo, A. L. Carvalho, And Gencapo, validation of methylation markers for diagnosis of oral cavity cancer. Eur. J. Cancer 51, 632–641 (2015). doi: 10.1016/j.ejca.2015.01.060 CrossRefPubMedGoogle Scholar
- 2.A.K. Markopoulos, Current aspects on oral squamous cell carcinoma. Open Dent. J. 6, 126–130 (2012) doi: 10.2174/1874210601206010126
- 4.K. Mohankumar, S. Pajaniradje, S. Sridharan, V. K. Singh, L. Ronsard, A. C. Banerjea, B. C. Selvanesan, M. S. Coumar, L. Periyasamy, R. Rajagopalan, Apoptosis induction by an analog of curcumin (BDMC-A) in human laryngeal carcinoma cells through intrinsic and extrinsic pathways. Cell. Oncol. 37, 439–454 (2014). doi: 10.1007/s13402-014-0207-3 CrossRefGoogle Scholar
- 6.T. Nakaoka, A. Ota, T. Ono, S. Karnan, H. Konishi, A. Furuhashi, Y. Ohmura, Y. Yamada, Y. Hosokawa, Y. Kazaoka, Combined arsenic trioxide-cisplatin treatment enhances apoptosis in oral squamous cell carcinoma cells. Cell. Oncol. 37, 119–129 (2014). doi: 10.1007/s13402-014-0167-7 CrossRefGoogle Scholar
- 7.Y. Tokumaru, K. Yamashita, M. Osada, S. Nomoto, D. I. Sun, Y. Xiao, M. O. Hoque, W. H. Westra, J. A. Califano, D. Sidransky, Inverse correlation between cyclin A1 hypermethylation and p53 mutation in head and neck cancer identified by reversal of epigenetic silencing. Cancer Res. 64, 5982–5987 (2004). doi: 10.1158/0008-5472.CAN-04-0993 CrossRefPubMedGoogle Scholar
- 10.R. J. Nobre, E. Cruz, O. Real, L. P. de Almeida, T. C. Martins, Characterization of common and rare human papillomaviruses in Portuguese women by the polymerase chain reaction, restriction fragment length polymorphism and sequencing. J. Med. Virol. 82, 1024–1032 (2010). doi: 10.1002/jmv.21756 CrossRefPubMedGoogle Scholar
- 11.A. O. Nygren, N. Ameziane, H. M. Duarte, R. N. Vijzelaar, Q. Waisfisz, C. J. Hess, J. P. Schouten, A. Errami, Methylation-specific MLPA (MS-MLPA): simultaneous detection of CpG methylation and copy number changes of up to 40 sequences. Nucleic Acids Res. 33, e128 (2005). doi: 10.1093/nar/gni127 CrossRefPubMedPubMedCentralGoogle Scholar
- 12.I. P. Ribeiro, F. Marques, F. Caramelo, J. Ferrao, H. Prazeres, M. J. Juliao, W. Rifi, S. Savola, J. B. de Melo, I. P. Baptista, I. M. Carreira, Genetic imbalances detected by multiplex ligation-dependent probe amplification in a cohort of patients with oral squamous cell carcinoma-the first step towards clinical personalized medicine. Tumour Biol. 35, 4687–4695 (2014). doi: 10.1007/s13277-014-1614-9 PubMedGoogle Scholar
- 13.I. P. Ribeiro, F. Marques, F. Caramelo, J. Pereira, M. Patricio, H. Prazeres, J. Ferrao, M. J. Juliao, M. Castelo-Branco, J. B. de Melo, I. P. Baptista, I. M. Carreira, Genetic gains and losses in oral squamous cell carcinoma: impact on clinical management. Cell. Oncol. 37, 29–39 (2014). doi: 10.1007/s13402-013-0161-5 CrossRefGoogle Scholar
- 14.M. Chmelarova, E. Dvorakova, J. Spacek, J. Laco, M. Mzik, V. Palicka, Promoter methylation of GATA4, WIF1, NTRK1 and other selected tumour suppressor genes in ovarian cancer. Folia Biol. 59, 87–92 (2013)Google Scholar
- 15.S. Maruya, J. P. Issa, R. S. Weber, D. I. Rosenthal, J. C. Haviland, R. Lotan, A. K. El-Naggar, Differential methylation status of tumor-associated genes in head and neck squamous carcinoma: incidence and potential implications. Clin. Cancer Res. 10, 3825–3830 (2004). doi: 10.1158/1078-0432.CCR-03-0370 CrossRefPubMedGoogle Scholar
- 19.M. Federico and L. Bagella, Histone deacetylase inhibitors in the treatment of hematological malignancies and solid tumors. J. Biomed. Biotechnol. 2011, 475641 (2011) doi: 10.1155/2011/475641
- 20.Y. Oji, H. Yamamoto, M. Nomura, Y. Nakano, A. Ikeba, S. Nakatsuka, S. Abeno, E. Kiyotoh, T. Jomgeow, M. Sekimoto, R. Nezu, Y. Yoshikawa, Y. Inoue, N. Hosen, M. Kawakami, A. Tsuboi, Y. Oka, H. Ogawa, S. Souda, K. Aozasa, M. Monden, H. Sugiyama, Overexpression of the Wilms’ tumor gene WT1 in colorectal adenocarcinoma. Cancer Sci. 94, 712–717 (2003)CrossRefPubMedGoogle Scholar
- 21.H. Sugiyama, WT1 (Wilms’ tumor gene 1): biology and cancer immunotherapy. Jpn. J. Clin. Oncol. 40, 377–387 (2010) doi: 10.1093/jjco/hyp194
- 24.S. Yip, J. Miao, D. P. Cahill, A. J. Iafrate, K. Aldape, C. L. Nutt, D. N. Louis, MSH6 mutations arise in glioblastomas during temozolomide therapy and mediate temozolomide resistance. Clin. Cancer Res. 15, 4622–4629 (2009). doi: 10.1158/1078-0432.CCR-08-3012 CrossRefPubMedPubMedCentralGoogle Scholar
- 25.I. Peters, N. Dubrowinskaja, M. Kogosov, M. Abbas, J. Hennenlotter, C. von Klot, A. S. Merseburger, A. Stenzl, R. Scherer, M. A. Kuczyk, J. Serth, Decreased GATA5 mRNA expression associates with CpG island methylation and shortened recurrence-free survival in clear cell renal cell carcinoma. BMC Cancer 14, 101 (2014). doi: 10.1186/1471-2407-14-101 CrossRefPubMedPubMedCentralGoogle Scholar
- 26.I. Peters, K. Gebauer, N. Dubrowinskaja, F. Atschekzei, M. W. Kramer, J. Hennenlotter, H. Tezval, M. Abbas, R. Scherer, A. S. Merseburger, A. Stenzl, M. A. Kuczyk, J. Serth, GATA5 CpG island hypermethylation is an independent predictor for poor clinical outcome in renal cell carcinoma. Oncol. Rep. 31, 1523–1530 (2014). doi: 10.3892/or.2014.3030 PubMedPubMedCentralGoogle Scholar
- 28.R. Guerrero-Preston, C. Michailidi, L. Marchionni, C. R. Pickering, M. J. Frederick, J. N. Myers, S. Yegnasubramanian, T. Hadar, M. G. Noordhuis, V. Zizkova, E. Fertig, N. Agrawal, W. Westra, W. Koch, J. Califano, V. E. Velculescu, D. Sidransky, Key tumor suppressor genes inactivated by "greater promoter" methylation and somatic mutations in head and neck cancer. Epigenetics 9, 1031–1046 (2014). doi: 10.4161/epi.29025 CrossRefPubMedPubMedCentralGoogle Scholar
- 31.K. T. Robbins, G. Clayman, P. A. Levine, J. Medina, R. Sessions, A. Shaha, P. Som, G. T. Wolf, H. American, S. Neck, O.-H. American Academy, Of and S. Neck, neck dissection classification update: revisions proposed by the American head and neck society and the American Academy of Otolaryngology-Head and Neck Surgery. Arch. Otolaryngol. Head Neck Surg. 128, 751–758 (2002)CrossRefGoogle Scholar
- 32.Cancer Genome Atlas Network, comprehensive genomic characterization of head and neck squamous cell carcinomas. Nature 517, 576–582 (2015) doi: 10.1038/nature14129